There is a bidirectional pathophysiological interaction between the heart and the kidneys, with heart failure and chronic kidney disease often causing or worsening the other

Sodium-glucose cotransporter 2 inhibitors were initially approved for treatment of Type 2 diabetes but have since demonstrated significant cardiorenal benefits to patients with and without Type 2 diabetes; however, the mechanisms via which these benefits are imparted are largely unknown

We present three key SGLT2i mechanisms via which this class of therapeutics imparts its cardiorenal benefits; these include improvement in kidney function and tissue oxygen delivery, vascular health and function and metabolic health

The use of SGLT2i therapy in treating HF and CKD in individuals with and without T2D has a marked impact, reducing the risk associated with worsening of these conditions